MiR-221 accentuates IFN's anti-HCV effect by downregulating SOCS1 and SOCS3

Virology

Volumn 462-463, Issue 1, 2014, Pages 343-350

  Xu, Gang ^a   Yang, Fang ^b   Ding, Cui Ling ^a   Wang, Jing ^c   Zhao, Ping ^a   Wang, Wen ^a   Ren, Hao ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b FUZHOU GENERAL HOSPITAL   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

HCV; IFN ; Mir 221; SOCS1; SOCS3

Indexed keywords

ALPHA INTERFERON; INTERFERON; JANUS KINASE; MICRORNA 221; NONSTRUCTURAL PROTEIN 5A; STAT PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; SUPPRESSOR OF CYTOKINE SIGNALING 3; VIRUS RNA;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; DRUG TARGETING; EMBRYO; FEMALE; GENE EXPRESSION; GENETIC TRANSFECTION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MIDDLE AGED; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION; VIRUS INHIBITION; VIRUS REPLICATION;

HCV; IFN-Α; MIR-221; SOCS1; SOCS3;

ADULT; AGED; CELL LINE; DOWN-REGULATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MICRORNAS; MIDDLE AGED; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS;

EID: 84904265622     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2014.06.024     Document Type: Article

References (50)

1. Bai S., et al. MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib. J. Biol. Chem. 2009, 284:32015-32027.
2. Bala S., et al. MicroRNA-155 expression in the serum and peripheral monocytes in chronic HCV infection. J. Transl. Med. 2012, 10:151.
3. Berkhout B., Jeang K.T. RISCy business: microRNAs, pathogenesis, and viruses. J. Biol. Chem. 2007, 282:26641-26645.
4. Bowen D.G., Walker C.M. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 2005, 436:946-952.
5. Braconi C., et al. Hepatitis C virus proteins modulate microRNA expression and chemosensitivity in malignant hepatocytes. Clin. Cancer Res. 2010, 16:957-966.
6. Callegari E., et al. Liver tumorigenicity promoted by microRNA-221 in a mouse transgenic model. Hepatology 2012, 56:1025-1033.
7. Cardoso A.L., Guedes J.R., Pereira de Almeida L, Pedroso de Lima MC MiR-155 modulates microglia-mediated immune response by down-regulating SOCS-1 and promoting cytokine and nitric oxide production. Immunology 2012, 135:73-88.
8. Chang J., et al. Liver-specific microRNA miR-122 enhances the replication of hepatitis C virus in nonhepatic cells. J. Virol. 2008, 82:8215-8223.
9. Cheng J.C., et al. Let-7b is a novel regulator of hepatitis C virus replication. Cell. Mol. Life Sci. 2012, 69:2621-2633.
10. Chisari F.V. Unscrambling hepatitis C virus-host interactions. Nature 2005, 436:930-932.
11. Diaz G., et al. Identification of microRNAs specifically expressed in hepatitis C virus-associated hepatocellular carcinoma. Int. J. Cancer. 2013, 133:816-824.
12. Fan C.G., et al. MiR-122 inhibits viral replication and cell proliferation in hepatitis B virus related hepatocellular carcinoma and targets NDRG3. Oncol. Rep. 2011, 26:1281-1286.
13. Fornari F., et al. MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene 2008, 27:5651-5661.
14. Gale M., Foy E.M. Evasion of intracellular host defence by hepatitis C virus. Nature 2005, 436:939-945.
15. Garaigorta U., Chisari F.V. Hepatitis C virus blocks interferon effector function by inducing protein kinase R phosphorylation. Cell Host Microbe 2009, 6:513-522.
16. Garofalo M., Quintavalle C., Romano G., Croce C.M., Condorelli G. MiR221/222 in cancer: their role in tumor progression and response to therapy. Curr. Mol. Med. 2012, 12:27-33.
17. Gramantieri L., et al. MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality. Clin. Cancer Res. 2009, 15:5073-5081.
18. Hsu S.H., et al. Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J. Clin. Invest. 2012, 122:2871-2883.
19. Ishida H., et al. Alterations in microRNA expression profile in HCV-infected hepatoma cells: involvement of miR-491 in regulation of HCV replication via the PI3 kinase/Akt pathway. Biochem. Biophys. Res. Commun. 2011, 412:92-97.
20. Jangra R.K., Yi M., Lemon S.M. Regulation of hepatitis C virus translation and infectious virus production by the microRNA miR-122. J. Virol. 2010, 84:6615-6625.
21. Janssen H.L., et al. Treatment of HCV infection by targeting microRNA. New Engl. J. Med. 2013, 368:1685-1694.
22. Jopling C.L., Yi M., Lancaster A.M., Lemon S.M., Sarnow P. Modulation of hepatitis C virus RNA abundance by a liver-specifi{ligature}cMicroRNA. Science 2005, 309:1577-1581.
23. Kumar A. MicroRNA in HCV infection and liver cancer. Biochim.Biophys. Acta 2011, 1809:694-699.
24. Lanford R.E., et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 2010, 327:198-201.
25. Lindenbach B.D., et al. Complete replication of hepatitis C virus in cell culture. Science 2005, 309:623-626.
26. Liu H.M., Gale M. Hepatitis C virus evasion from RIG-I-dependent hepatic innate immunity. Gastroenterol. Res. Pract. 2010, 2010:548390.
27. Lu C., et al. MiR-221 and miR-155 regulate human dendritic cell development, apoptosis, and IL-12 production through targeting of p27kip1, KPC1, and SOCS-1. Blood 2011, 117:4293-4303.
28. Marquez R.T., et al. Correlation between microRNA expression levels and clinical parameters associated with chronic hepatitis C viral infection in humans. Lab. Invest. 2010, 90:1727-1736.
29. Miyoshi H., et al. Hepatitis C virus core protein exerts an inhibitory effect on suppressor of cytokine signaling (SOCS)-1 gene expression. J. Hepatol. 2005, 43:757-763.
30. Moffatt C.E., Lamont R.J. Porphyromonas gingivalis induction of microRNA-203 expression controls suppressor of cytokine signaling 3 in gingival epithelial cells. Infect. Immun. 2011, 79:2632-2637.
31. Moorman J., et al. Abnormal B-cell activation associated with TALL-1 over-expression and SOCS-1 suppression during chronic hepatitis C virus infection. Immunology 2009, 128:227-235.
32. Narbus C.M., et al. HepG2 cells expressing microRNA miR-122 support the entire hepatitis C virus life cycle. J. Virol. 2011, 85:12087-12092.
33. Negrini M., Gramantieri L., Sabbioni S., Croce C.M. microRNA involvement in hepatocellular carcinoma. Anticancer Agents Med. Chem. 2011, 11:500-521.
34. Ogawa T., et al. MicroRNA-221/222 upregulation indicates the activation of stellate cells and the progression of liver fibrosis. Gut 2012, 61:1600-1609.
35. O'Connell R.M., Taganov K.D., Boldin M.P., Cheng G., Baltimore D. MicroRNA-155 is induced during the macrophage infl{ligature}ammatory response. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:1604-1609.
36. Park J.K., et al. MiR-221 silencing blocks hepatocellular carcinoma and promotes survival. Cancer Res. 2011, 71:7608-7616.
37. Pineau P., et al. MiR-221 overexpression contributes to liver tumorigenesis. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:264-269.
38. Roberts A.P., Lewis A.P., Jopling C.L. MiR-122 activates hepatitis C virus translation by a specialized mechanism requiring particular RNA components. Nucleic Acids Res. 2011, 39:7716-7729.
39. Santhekadur P.K., et al. Multifunction protein staphylococcal nuclease domain containing 1 (SND1) promotes tumor angiogenesis in human hepatocellular carcinoma through novel pathway that involves nuclear factor κB and miR-221. J. Biol. Chem. 2012, 287:13952-13958.
40. Sendi H. Dual role of miR-122 in molecular pathogenesis of viral hepatitis. Hepat. Mon. 2012, 12:312-314.
41. Taganov K.D., Boldin M.P., Chang K.J., Baltimore D. NF-kappaB-dependent induction of microRNA miR-146, an in hibitor targeted to signaling proteins of innate immune responses. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:12481-12486.
42. Tang Y., et al. MicroRNA-146A contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. Arthritis Rheumatol. 2009, 60:1065-1075.
43. Walsh M.J., et al. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut 2006, 55:529-535.
44. Wang S., et al. Loss of microRNA 122 expression in patients with hepatitis B enhances hepatitis B virus replication through cyclin G (1) -modulated P53 activity. Hepatology 2012, 55:730-741.
45. Watanabe Y., Kishi A., Yachie N., Kanai A., Tomita M. Computational analysis of microRNA-mediated antiviral defense in humans. FEBS Lett. 2007, 581:4603-4610.
46. Witwer K.W., Sisk J.M., Gama L., Clements J.E. MicroRNA regulation of IFN-beta protein expression: rapid and sensitive modulation of the innate immune response. J. Immunol. 2010, 184:2369-2376.
47. Xu J., et al. MicroRNA-122 suppresses cell proliferation and induces cell apoptosis in hepatocellular carcinoma by directly targeting Wnt/β-catenin pathway. Liver Int. 2012, 32:752-760.
48. Yasukawa H., et al. The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop. EMBO J. 1999, 18:1309-1320.
49. Yoshimura A. Regulation of cytokine signaling by the SOCS and Spred family proteins. Keio J. Med. 2009, 58:73-83.
50. Zhang G., Wang Q., Xu R. Therapeutics based on microRNA: a new approach for liver cancer. Curr. Genomics. 2010, 11:311-325.